R&D Industry Finds Biosimilar Interchangeability Statement By EU Regulators ‘Concerning’
A joint statement from the European Medicines Agency and Heads of Medicines Agencies on biosimilar interchangeability is “concerning,” says Europe’s R&D-based industry federation, EFPIA.
You may also be interested in...
US FDA India country director Dr Sarah McMullen provides a fact check at a recent conclave to dispel the notion that interchangeable biosimilars are safer and more effective than other approved biosimilars.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.
Brazil’s health technology assessment institute is to incorporate cost-effectiveness thresholds into its decision making.